secwatch.observer — SEC 8-K summary
======================================

Issuer:     Relay Therapeutics, Inc. (RLAY)
CIK:        0001812364
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001193125-26-076617
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relay Therapeutics reports Q4 net loss $0.32/share; cash $554.5M; zovegalisib milestones in 2026
--------------------------------------------------------------------------------

- Q4 2025 net loss $54.9M ($0.32/share) vs $76.0M ($0.45) in Q4 2024; full year net loss $276.5M ($1.61/share).
- Cash, cash equivalents and investments $554.5M at Dec 31 2025, down from $781.3M; runway into 2029.
- Revenue $7.0M in Q4 2025 (Elevar license) vs $0 in Q4 2024; full year revenue $15.4M.
- Zovegalisib Phase 1/2 breast cancer data at ESMO TAT March 16 in 57 patients at Phase 3 dose.
- Initial vascular anomalies data expected 1H 2026; pediatric cohort in ReInspire trial opened early.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1812364/000119312526076617/0001193125-26-076617-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1812364/000119312526076617/rlay-20260226.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-076617

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer